To include your compound in the COVID-19 Resource Center, submit it here.

Inotuzumab ozogamicin: Additional Phase II data

Additional data from the ongoing, open-label, international Phase II Study 2001 trial in 59 evaluable patients who have relapsed or are refractory to rituximab and chemotherapy or anti-

Read the full 283 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE